Thirugnanasundralingam Vaisnavi, McGrath Shannon, Roberts Jay, Corcoran Niall
Department of Urology, Western Health, Footscray, VIC, Australia.
Radiol Case Rep. 2024 Jul 16;19(10):4122-4126. doi: 10.1016/j.radcr.2024.06.021. eCollection 2024 Oct.
A 54-year-old male with biopsy-confirmed Gleason 4+4 prostate cancer underwent F-DCFPyL-PSMA PET scan to identify occult metastatic disease. This scan revealed abnormal radionuclide uptake not only in the prostate but also within the patient's vasculature. The scan was repeated after a week with a separate tracer batch, yielding the same result. Standard staging was performed using computed tomography and a Technetium-99 bone scan, revealing no metastatic disease. The patient's protein S deficiency is thought to have caused this peculiar tracer distribution. With the advent of PSMA PET for staging in prostate cancer, clinicians must be familiar with situations that may render unusual results.
一名经活检确诊为Gleason 4+4前列腺癌的54岁男性接受了F-DCFPyL-PSMA PET扫描,以确定隐匿性转移性疾病。该扫描显示,不仅前列腺内有异常放射性核素摄取,患者的脉管系统内也有。一周后使用另一批示踪剂重复扫描,结果相同。采用计算机断层扫描和锝-99骨扫描进行标准分期,未发现转移性疾病。患者的蛋白S缺乏被认为是导致这种特殊示踪剂分布的原因。随着PSMA PET用于前列腺癌分期的出现,临床医生必须熟悉可能产生异常结果的情况。